Clinical Trials Directory

Trials / Completed

CompletedNCT02580370

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
450 (actual)
Sponsor
Revance Therapeutics, Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.

Conditions

Interventions

TypeNameDescription
BIOLOGICALBotulinum toxin type ATopical botulinum toxin type A
BIOLOGICALPlacebo comparatorTopical placebo comparator

Timeline

Start date
2015-09-01
Primary completion
2016-07-01
Completion
2016-08-01
First posted
2015-10-20
Last updated
2016-09-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02580370. Inclusion in this directory is not an endorsement.